novo nordisk glp-1 receptor agonists weight management diabetes treatments as for Type 2 GLP-1 Agonists For Obesity In

Native GLP-1 has a short half-life and is degraded in minutes by dipeptidyl-peptidase 4 (DPP-4), mediated by alanine at position 8 [16]

doi: 10.2337/dc20-2151

These include personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, history of pancreatitis, severe gastrointestinal disease, and pregnancy or plans to become pregnant

Specifically, Saxenda is indicated for chronic weight management in obese adults (BMI 30) or those merely overweight with a BMI 27 and a weight-related comorbidity such as hypertension, dyslipidemia, or diabetes

There is interest in GLP-1 agonists and their ability to either reduce atherosclerotic plaque burden or the potential for plaque disruption- recognized as a proximate cause of arterial thrombotic events

obesity and diabetes